Jonathan Skipper

2.4k total citations · 1 hit paper
16 papers, 2.0k citations indexed

About

Jonathan Skipper is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Jonathan Skipper has authored 16 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 12 papers in Molecular Biology and 3 papers in Oncology. Recurrent topics in Jonathan Skipper's work include Immunotherapy and Immune Responses (15 papers), vaccines and immunoinformatics approaches (8 papers) and T-cell and B-cell Immunology (8 papers). Jonathan Skipper is often cited by papers focused on Immunotherapy and Immune Responses (15 papers), vaccines and immunoinformatics approaches (8 papers) and T-cell and B-cell Immunology (8 papers). Jonathan Skipper collaborates with scholars based in United States, Germany and Australia. Jonathan Skipper's co-authors include Víctor H. Engelhard, Donald F. Hunt, Jeffrey Shabanowitz, Craig L. Slingluff, Andrea L. Cox, Ye Chen, Robert Henderson, Timothy L. Darrow, Ronald C. Hendrickson and Pamela H. Gulden and has published in prestigious journals such as Science, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Jonathan Skipper

16 papers receiving 1.9k citations

Hit Papers

Identification of a Peptide Recognized by Five Melanoma-S... 1994 2026 2004 2015 1994 200 400 600

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jonathan Skipper United States 12 1.7k 919 551 216 197 16 2.0k
Dongshu Chen United States 19 1.7k 1.0× 1.7k 1.8× 1.1k 2.0× 357 1.7× 176 0.9× 22 2.7k
Angela M. Krackhardt Germany 23 965 0.6× 769 0.8× 965 1.8× 252 1.2× 91 0.5× 58 1.8k
Solam Tsang United States 10 1.6k 1.0× 1.3k 1.5× 628 1.1× 360 1.7× 53 0.3× 11 2.2k
Stefan Stevanović Germany 15 929 0.6× 596 0.6× 270 0.5× 161 0.7× 120 0.6× 27 1.3k
Silvia von Mensdorff‐Pouilly Netherlands 28 900 0.5× 1.2k 1.3× 525 1.0× 841 3.9× 81 0.4× 58 2.0k
Kent S. Boles United States 12 1.3k 0.8× 384 0.4× 453 0.8× 91 0.4× 133 0.7× 13 1.7k
Raymond Frade France 25 689 0.4× 551 0.6× 548 1.0× 224 1.0× 180 0.9× 72 1.6k
E Tatsumi Japan 21 685 0.4× 639 0.7× 612 1.1× 185 0.9× 313 1.6× 82 1.8k
J. Hilgers Netherlands 15 576 0.3× 871 0.9× 336 0.6× 647 3.0× 64 0.3× 25 1.3k
Angela L. Zarling United States 13 837 0.5× 565 0.6× 304 0.6× 177 0.8× 90 0.5× 17 1.1k

Countries citing papers authored by Jonathan Skipper

Since Specialization
Citations

This map shows the geographic impact of Jonathan Skipper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Skipper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Skipper more than expected).

Fields of papers citing papers by Jonathan Skipper

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Skipper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Skipper. The network helps show where Jonathan Skipper may publish in the future.

Co-authorship network of co-authors of Jonathan Skipper

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Skipper. A scholar is included among the top collaborators of Jonathan Skipper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Skipper. Jonathan Skipper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Sharma, Sameer, Feng Qian, Bernadette Keitz, et al.. (2005). A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer. Gynecologic Oncology. 99(1). 183–188. 29 indexed citations
2.
Singhal, Pankaj, Feng Qian, Bernadette Keitz, et al.. (2005). TPTE “Cancer/Testis” antigen is a candidate target for immunotherapy in epithelial ovarian carcinoma. Journal of Clinical Oncology. 23(16_suppl). 2583–2583. 1 indexed citations
3.
Odunsi, Kunle, Feng Qian, Sacha Gnjatic, et al.. (2005). Immunization of ovarian cancer patients with an NY-ESO-1 peptide of dual MHC class I and II specificities plus incomplete Freund adjuvant induces simultaneous humoral, CD4+ and CD8+ T-cell responses. Journal of Clinical Oncology. 23(16_suppl). 5040–5040. 2 indexed citations
4.
Huarte, Eduardo, Julia Karbach, Sacha Gnjatic, et al.. (2004). HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones. PubMed. 4. 15–15. 11 indexed citations
5.
Uenaka, Akiko, Sanda Win, Motoyuki Tanaka, et al.. (2003). Cryptic CTL Epitope on a Murine Sarcoma Meth A Generated by Exon Extension as a Novel Mechanism. The Journal of Immunology. 170(9). 4862–4868. 6 indexed citations
6.
Jäger, Elke, Julia Karbach, Sacha Gnjatic, et al.. (2002). Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. PubMed. 2. 12–12. 28 indexed citations
7.
Slingluff, Craig L., Teresa A. Colella, Lee W. Thompson, et al.. (2000). Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunology Immunotherapy. 48(12). 661–672. 78 indexed citations
8.
Skipper, Jonathan, Pamela H. Gulden, Ronald C. Hendrickson, et al.. (1999). Mass‐spectrometric evaluation of HLA‐A*0201‐associated peptides identifies dominant naturally processed forms of CTL epitopes from MART‐1 and gp100. International Journal of Cancer. 82(5). 669–677. 80 indexed citations
9.
Kittlesen, David J., Lee W. Thompson, Pamela H. Gulden, et al.. (1998). Human Melanoma Patients Recognize an HLA-A1-Restricted CTL Epitope from Tyrosinase Containing Two Cysteine Residues: Implications for Tumor Vaccine Development. The Journal of Immunology. 160(5). 2099–2106. 104 indexed citations
10.
Springer, Sebastian, et al.. (1998). Fast Association Rates Suggest a Conformational Change in the MHC Class I Molecule H-2Dbupon Peptide Binding. Biochemistry. 37(9). 3001–3012. 61 indexed citations
11.
Dubey, Purnima, Ronald C. Hendrickson, Stephen C. Meredith, et al.. (1997). The Immunodominant Antigen of an Ultraviolet-induced Regressor Tumor Is Generated by a Somatic Point Mutation in the DEAD Box Helicase p68. The Journal of Experimental Medicine. 185(4). 695–706. 109 indexed citations
12.
Skipper, Jonathan, Ronald C. Hendrickson, Pamela H. Gulden, et al.. (1996). An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.. The Journal of Experimental Medicine. 183(2). 527–534. 346 indexed citations
13.
Skipper, Jonathan, Ronald C. Hendrickson, Nancy L. Harthun, et al.. (1996). Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. The Journal of Immunology. 157(11). 5027–5033. 84 indexed citations
14.
Haan, Joke M. M. den, Nicholas E. Sherman, Els Blokland, et al.. (1995). Identification of a Graft Versus Host Disease-Associated Human Minor Histocompatibility Antigen. Science. 268(5216). 1476–1480. 334 indexed citations
15.
Cox, Andrea L., Jonathan Skipper, Ye Chen, et al.. (1994). Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines. Science. 264(5159). 716–719. 677 indexed citations breakdown →
16.
Solomon, H. J., Martin H.N. Tattersall, James J. Campbell, et al.. (1986). Chemotherapy of advanced ovarian adenocarcinoma: A randomized comparison of combination versus sequential therapy using chlorambucil and cisplatin. Gynecologic Oncology. 23(1). 1–13. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026